Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
03-07 May, 2026
Not Confirmed
Not Confirmed
04-07 May, 2026
Vitafoods EuropeVitafoods Europe
Not Confirmed
Not Confirmed
05-07 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Arvo
Not Confirmed
Contact SupplierArvo
Industry Trade Show
Not Confirmed
03-07 May, 2026
Industry Trade Show
Not Confirmed
04-07 May, 2026
Vitafoods EuropeVitafoods Europe
Industry Trade Show
Not Confirmed
05-07 May, 2026
Digital content
NEWS #PharmaBuzz
28 Apr 2026
// FIRSTWORD PHARMA
16 Apr 2026
// FIRSTWORD PHARMA
13 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/13/3272888/0/en/Sana-Biotechnology-and-Mayo-Clinic-Announce-Strategic-Collaboration-Focused-on-Improving-Care-in-Type-1-Diabetes-and-Accelerating-Development-of-SC451.html
10 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pendulum-therapeutics-expands-clinical-collaboration-to-advance-microbiome-research-in-womens-health-and-dermatology-302739314.html
25 Mar 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/medtech/endogenex-nets-50m-carry-intestinal-diabetes-procedure-fda
24 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/anti-aging-protein-research-takes-a-step-forward-with-cell-cloning-302723584.html
Drugs in Development
Details:
Tavneos (Avacopan) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of diffuse alveolar hemorrhage.
Lead Product(s): Avacopan
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tavneos
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2026
Lead Product(s) : Avacopan
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
Details : Tavneos (Avacopan) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of diffuse alveolar hemorrhage.
Product Name : Tavneos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2026
Details:
The collaboration aims to advance cell & gene therapy for type 1 diabetes with lead product SC451.
Lead Product(s): SC451
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Recipient: Sana Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2026
Lead Product(s) : SC451
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Sana Biotechnology, Mayo Clinic Collaborate on Type 1 Diabetes Care, SC451 Development
Details : The collaboration aims to advance cell & gene therapy for type 1 diabetes with lead product SC451.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 13, 2026
Details:
Ipilimumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of carcinoma, renal cell.
Lead Product(s): Ipilimumab,Nivolumab,VSV-IFNβ-NIS
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2026
Lead Product(s) : Ipilimumab,Nivolumab,VSV-IFNβ-NIS
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell...
Details : Ipilimumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of carcinoma, renal cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 03, 2026
Details:
Bimekizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pityriasis Rubra Pilaris.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2026
Lead Product(s) : Bimekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP
Details : Bimekizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pityriasis Rubra Pilaris.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 27, 2026
Details:
Nicotine is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Smoking Cessation.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: National Cancer Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2026
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Details : Nicotine is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Smoking Cessation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2026
Details:
Spironolactone is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of aortic aneurysm, thoracic.
Lead Product(s): Spironolactone
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2026
Lead Product(s) : Spironolactone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HEART: Pilot Randomized Controlled Trial
Details : Spironolactone is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of aortic aneurysm, thoracic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2026
Details:
Retifanlimab is a antibody drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of oligodendroglioma.
Lead Product(s): Retifanlimab,Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2026
Lead Product(s) : Retifanlimab,Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Retifanlimab is a antibody drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of oligodendroglioma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 12, 2026
Details:
Zoladex (Goserelin Acetate) is a peptide drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Lead Product(s): Goserelin Acetate
Therapeutic Area: Oncology Brand Name: Zoladex
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2026
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zoladex (Goserelin Acetate) is a peptide drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Product Name : Zoladex
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 10, 2026
Details:
Imdur (Isosorbide Mononitrate) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of digestive system neoplasms.
Lead Product(s): Isosorbide Mononitrate,Diltiazem Hydrochloride,Fluorouracil,Capecitabine
Therapeutic Area: Oncology Brand Name: Imdur
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2026
Lead Product(s) : Isosorbide Mononitrate,Diltiazem Hydrochloride,Fluorouracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Imdur (Isosorbide Mononitrate) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of digestive system neoplasms.
Product Name : Imdur
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2026
Details:
18-F Fluoroethyl-L-Tyrosine is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of pituitary neoplasms.
Lead Product(s): 18-F Fluoroethyl-L-Tyrosine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Radiolabeled Compound
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2026
Lead Product(s) : 18-F Fluoroethyl-L-Tyrosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
Details : 18-F Fluoroethyl-L-Tyrosine is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of pituitary neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
March 09, 2026
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Mayo Clinic is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find Ribavirin bulk offered by Mayo Clinic
Find COMMITTEE ON SAFETY OF THERAPEUTIC AGENTS bulk offered by Mayo Clinic
Find HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (IMMUNEX), AEROSOL bulk offered by Mayo Clinic
Share 
